Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
This study has been completed.
Sponsor:
Regeneron Pharmaceuticals
Information provided by:
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00320814
First received: April 28, 2006
Last updated: June 8, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Macular Edema |
Drug: VEGF Trap-Eye |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients With Diabetic Macular Edema |
Resource links provided by NLM:
Genetics Home Reference related topics:
age-related macular degeneration
tumor necrosis factor receptor-associated periodic syndrome
X-linked juvenile retinoschisis
MedlinePlus related topics:
Edema
Drug Information available for:
Aflibercept
U.S. FDA Resources
Further study details as provided by Regeneron Pharmaceuticals:
Primary Outcome Measures:
- To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME) [ Time Frame: Assessments for safety and tolerablity are performed at each visit (Visit 1 - Visit 10) ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT) [ Time Frame: Assessments for CRT are performed at each visit (Visit 1 - Visit 10) by means of OCT. ] [ Designated as safety issue: No ]
- To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity [ Time Frame: Assessments for visual acuity are performed at each visit (Visit 1 - Visit 10). ] [ Designated as safety issue: No ]
| Enrollment: | 5 |
| Study Start Date: | April 2006 |
| Study Completion Date: | August 2007 |
| Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: VEGF Trap-Eye
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
|
Drug: VEGF Trap-Eye
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
|
Detailed Description:
This is an open label study. Initially, 5 patients with DME will receive an ITV injection of VEGF Trap into the study eye. Additional patients may be enrolled at the same or additional dose levels. Patients will be observed for six weeks following the injection for assessments of ocular and systemic safety.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of diabetes mellitus (type 1 or type 2).
- Best corrected E-ETDRS visual acuity score of ≥ 24 letters (i.e., 20/320 or better) and ≤ 73 letters (i.e., 20/40 or worse).
- On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.
- Retinal Thickness at the center point ≥ 250 microns.
- Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs.
Exclusion Criteria:
- History of any vitreous hemorrhage within 4 weeks prior to Visit 2 (Day 1).
- Macular edema due to causes other than diabetic macular edema. An eye should be considered ineligible: (1) if the macular edema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggests that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema.
- An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal condition).
- An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.).
- Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase 1 study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00320814
Locations
| United States, Maryland | |
| Baltimore, Maryland, United States, 21287 | |
| United States, North Carolina | |
| Charlotte, North Carolina, United States, 28210 | |
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
| Study Director: | Avner Ingerman, MD | Regeneron Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Avner Ingerman, MD/Medical Monitor, Regeneron Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00320814 History of Changes |
| Other Study ID Numbers: | VGFT-OD-0512 |
| Study First Received: | April 28, 2006 |
| Last Updated: | June 8, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Edema Macular Edema Signs and Symptoms Macular Degeneration |
Retinal Degeneration Retinal Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 21, 2013